Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a promising company with significant strengths, such as a strong recurring revenue stream and a global presence. However, investors should be aware of potential competition, pricing challenges, and market risks, as well as past FDA warnings. Despite these challenges, MiniMed's focus on innovation and their partnerships may lead to future growth.

Bears say

Minimed Group is facing significant challenges with its stock as the company operates in a highly competitive market, with many established players and new entrants vying for market share. The company's recent gross margin decline and projected near-term spend increase will put pressure on its financial performance. Additionally, the diabetes market is highly dependent on external factors, such as healthcare policies and regulations, which could pose a risk to the company's future growth. Furthermore, MiniMed's struggles with product development timelines could leave it at a disadvantage compared to its competitors.

MMED has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 9 analysts, MMED has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.